Dave Kern


Dave Kern, PhD
Director, Epidemiology
Janssen Research and Development
Email: dkern2@its.jnj.com

Dave Kern, PhD, is a directory of Epidemiology at Janssen Research and Development and a member of the Epidemiology Analytics group. His work mainly resides in Janssen’s neuroscience therapeutic area, with specific focus on Parkinson’s disease, multiple sclerosis, and opioid consortiums for the risk evaluation and mitigation strategy (REMS) and post marketing requirements. As a member of the OHDSI group, Dave is focused on expanding the capabilities of Atlas to appeal to a larger audience, taking part in initiatives for cohort characterization and healthcare cost and utilization. Dr. Kern also serves as an adjunct faculty member in Drexel University’s School of Public Health teaching courses in epidemiology and biostatistics.

Prior to joining Janssen in 2017, Dave spent seven years at the research company HealthCore where he led a team of researchers performing health economic and outcomes research studies for various pharmaceutical and device companies utilizing administrative claims data, physician and patient surveys, and medical chart reviews. Dave received his PhD in Epidemiology from Drexel University and his Master of Science in Biostatistics from Columbia University.

Stephenson JJ, Raval AD, Kern DM, Bae JP. Nonadherence to Basal Insulin Among Patients With Type 2 Diabetes in a US Managed Care Population: Results from a Patient Survey. Diabetes Obes Metab. 2018 Jun 21. doi: 10.1111/dom.13446.

Kern DM, Chang L, Sonawane K, Larmore CJ, Boytsov NN, Quimbo RA, Singer J, Hinton JT, Wu SJ, Araujo AB. Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured Population. Rheumatol Ther. 2018 May 30.

Kern DM, Barron JJ, Wu B, Ganetsky A, Willey VJ, Quimbo RA, Fisch MJ, Singer J, Nguyen A, Mamtani R. A Validation of Clinical Data Captured From a Novel Cancer Care Quality Program Directly Integrated with Administrative Claims Data. Pragmat Obs Res. 2017 Aug 26;8:149-155.

Olufade T, Zhou S, Anzalone D, Kern DM, Tunceli O, Cziraky MJ, Willey VJ. Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan. J Am Heart Assoc. May 2017;6(5).

Davis JR, Wu B, Kern DM, Tunceli O, Fox KM, Horton J, Legg RF, Trudo F. Impact of nonadherence to ICS/LABA therapy on COPD exacerbation rates and healthcare costs in a commercially-insured US population. Am Health Drug Benefits. April 2017;10(2):92-102.

Wu B, Bell K, Stanford A, Kern DM, Tunceli O, Vupputuri S, Kalsekar I, Willey V. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns – NHANES 2007-2012. BMJ Open Diab Res Care. Apr 2016; 11(4):e000154

Kern DM, Mellstrom C, Hunt PR, Tunceli O, Wu B, Westergaard M, Hammar N. Long-term cardiovascular risk and costs for myocardial infarction survivors in a US commercially insured population. Curr Med Res Opin. Apr 2016; 32(4):703-11.

Trudo F, Davis J, Kern DM, Tunceli O, Zhou S, Graham E, Strange C, Williams SA. Comparative effectiveness of budesonide/formoterol combination (BFC) and tiotropium bromide among chronic obstructive pulmonary disease (COPD) patients new to these controller treatments. Int J Chron Obstruct Pulmon Dis. Sep 2015; 10(1):2055-2066.

Kern DM, Davis J, Williams SA, Tunceli O, Wu B, Graham E, Strange C, Trudo F. Validation of an administrative claims-based diagnostic code for pneumonia in a commercially insured COPD population. Int J Chron Obstruct Pulmon Dis. Jul 2015; 10(1):1417-1425.

Kern DM, Davis J, Williams SA, Tunceli O, Wu B, Hollis S, Strange C, Trudo F. Comparative Effectiveness of Budesonide/Formoterol Combination and Fluticasone/Salmeterol Combination among Chronic Obstructive Pulmonary Disease Patients New to Controller Treatment: A US Administrative Claims Database Study. Repir Res. Apr 2015; 16(1):52